KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Accounts Payables (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Accounts Payables data on record, last reported at $15.2 million in Q4 2025.

  • For Q4 2025, Accounts Payables fell 20.82% year-over-year to $15.2 million; the TTM value through Dec 2025 reached $15.2 million, down 20.82%, while the annual FY2025 figure was $15.2 million, 20.82% down from the prior year.
  • Accounts Payables reached $15.2 million in Q4 2025 per PCRX's latest filing, down from $17.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $30.1 million in Q2 2025 and bottomed at $7.9 million in Q3 2021.
  • Average Accounts Payables over 5 years is $16.1 million, with a median of $15.5 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: tumbled 47.96% in 2024, then surged 157.98% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $10.5 million in 2021, then surged by 44.36% to $15.2 million in 2022, then increased by 3.14% to $15.7 million in 2023, then rose by 21.88% to $19.1 million in 2024, then fell by 20.82% to $15.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $15.2 million in Q4 2025, $17.7 million in Q3 2025, and $30.1 million in Q2 2025.